Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over

  • Technology appraisal guidance
  • TA1038
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators